ADXNZ Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.071 |
| 52 Week High | CHF0.20 |
| 52 Week Low | CHF0.038 |
| Beta | 1.82 |
| 1 Month Change | -62.13% |
| 3 Month Change | -2.20% |
| 1 Year Change | -46.62% |
| 3 Year Change | -95.12% |
| 5 Year Change | -95.92% |
| Change since IPO | -98.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADXNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.6% | 1.0% | 1.3% |
| 1Y | -46.6% | -21.4% | 6.1% |
Return vs Industry: ADXNZ underperformed the UK Biotechs industry which returned -22.3% over the past year.
Return vs Market: ADXNZ underperformed the UK Market which returned 5.5% over the past year.
Price Volatility
| ADXNZ volatility | |
|---|---|
| ADXNZ Average Weekly Movement | 35.0% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ADXNZ's share price has been volatile over the past 3 months.
Volatility Over Time: ADXNZ's weekly volatility has increased from 20% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| ADXNZ fundamental statistics | |
|---|---|
| Market cap | CHF9.11m |
| Earnings (TTM) | -CHF10.56m |
| Revenue (TTM) | CHF1.65m |
5.5x
P/S Ratio-0.9x
P/E RatioIs ADXNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADXNZ income statement (TTM) | |
|---|---|
| Revenue | CHF1.65m |
| Cost of Revenue | CHF6.94m |
| Gross Profit | -CHF5.29m |
| Other Expenses | CHF5.27m |
| Earnings | -CHF10.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 12, 2024
| Earnings per share (EPS) | -0.082 |
| Gross Margin | -321.08% |
| Net Profit Margin | -640.91% |
| Debt/Equity Ratio | 0% |
How did ADXNZ perform over the long term?
See historical performance and comparison